This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts Name Top Biotech Stocks for 2010: BioBuzz

"Third, valuations remain in the bottom quintile of their ten year ranges, reflecting near-universal negative sentiment today. Fourth, healthcare reform is reaching an end, of some sort, which so far does not impose a particularly onerous burden on companies in this group and should offer incremental volume, for some products at least, in 2011 or 2012 when expanded coverage is accessible."

Porges' picks for best and worst stock performance in 2010:

"While the best performers in biotech in 2009 were mid cap and emerging stocks such as Vertex, Human Genome Sciences, Dendreon (DNDN), Protalix (PLX), and Incyte, we find it hard to see those same names offering as much upside in 2010. The stocks with the greatest upside to our estimates for 2010 are Genzyme (GENZ), Gilead Sciences (GILD), and Celgene and the stocks with the greatest upside to our target prices are those names, plus Amgen (AMGN - Get Report), all having 20-40% upside potential at current levels. The stocks where we perceive the greatest risks to our forecasts and estimates are Alexion (ALXN) and Biogen Idec (BIIB)."

Lehman Brothers issued its 2010 biotech forecast Monday morning. Here's analyst Jim Birchenough's take on the sector and the firm's top picks:

"Opportunities for the U.S. biotechnology group are selective and we tend to prefer small-mid cap stocks over large-cap stocks overall in 1H10. Within the large cap group our rank order of preference is Amgen, Genzyme and Celgene as top picks with Gilead and Biogen Idec viewed less favorably. Top mid-cap picks include Amylin Pharmaceuticals (AMLN), Cephalon (CEPH), Human Genome Sciences, Onyx Pharmaceuticals (ONXX) and Regeneron Pharmaceuticals (REGN) while we are less positive on Theravance (THRX), OSI Pharmaceuticals and Zymogenetics (ZGEN).
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
ACOR $33.63 0.00%
AMGN $144.72 0.00%
CELG $102.45 0.00%
INCY $68.36 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs